Dr. Hsiao is the Chief Executive Officer, President and Co-Founder of Acepodia. He was awarded Dr. Y-T Lee Prize, which named after Nobel Laureate Dr. Lee, for his research achievement in Chemistry. Dr. Hsiao has extensive research experience in immune cell therapy development, which led to the discovery and invention of Acepodia’s novel cellular immunotherapy development platform, ACC (Antibody-Cell Conjugation) which was from Nobel Prize laureate-Professor Carolyn Bertozzi's pioneering work in the development of biorthogonal chemistry when Dr. Hsiao, Ph.D., worked at her lab. Dr. Hsiao earned his B.S. in Chemistry from National Taiwan University, and his Ph.D. in Chemistry and Molecular Cell Biology from the University of California, Berkeley.

Jennifer has more than 25 years of Quality and CMC experience for CAR-T cell therapy, Antibody therapeutics, and Antibody Drug Conjugates. Jennifer is now the VP of Quality at Acepodia Biotech, Inc., an allogeneic cell therapy company specialized in a patented Antibody Cell Conjugates platform, based in the San Francisco Bay Area and with Operations in Taiwan.

Before joining Acepodia, Jennifer was the Head of Quality at JW Therapeutics in China, working on the development of an autologous CAR-T cell therapy product RelmaCel, which was approved and launched in Sept 2021. Prior to joining JW in 2018, Jennifer worked at Abbvie for 2 years, Genentech for 10 years, and Tanox for 10 years in the US, led a team of scientists/Quality specialists responsible for various CMC and Quality aspects in developing multiple Antibody based therapeutics.

Jennifer earned her B.S. in Chemistry, and M.S. in Chemical Engineering from Tsinghua University in China, and Ph.D. in Chemical Engineering from Texas A&M University in the US.

Dr. Kurman has spent over forty years in the oncology drug development field. He is a board-certified medical oncologist who practiced community oncology and has participated as an investigator in oncology clinical trials sponsored by the National Cancer Institute. During his career in the pharmaceutical industry, he has held positions of progressive responsibility at Janssen Pharmaceutica, Cytogen Corporation, U.S. Bioscience, and Quintiles’ (now IQVIA) Oncology Therapeutics Division. During his career in the pharmaceutical industry, Dr. Kurman has been involved in the regulatory review or commercial launch of four new oncology products. Dr. Kurman received his B.A., summa cum laude in biology from Syracuse University and his M.D. from Cornell University Medical College. He has held teaching positions at New York University and Stevens Institute and is an entrepreneur-in-residence at the Yale Office of Cooperative Research and a mentor for the Weill Cornell Bioventure eLAB.  

YanDa is one of the founding members of Acepodia, currently serving as a key leader responsible for daily company operations. With a broad portfolio that includes HR, Legal, IT, general affairs, and procurement, he has been instrumental in scaling the company from 5 to nearly 100 employees.
Prior to his role at Acepodia, YanDa began his career as a researcher at the Development Center for Biotechnology (DCB), where he focused on therapeutic antibody screening and humanization. He later transitioned to the pharmaceutical industry, gaining valuable experience in sales and marketing at AstraZeneca (AZ) in Taiwan.
He holds a master's degree from the Institute of Biochemistry and Molecular Biology at National Yang-Ming University and a bachelor's degree from the Department of Forestry and Resource Conservation at National Taiwan University.

Mr. Wu is senior finance and management professional with extensive experience in publicly listed companies across multiple industries—including pharmaceuticals. Recognized for a rigorous command of corporate accounting and governance, with a deep ability to identify operational blind spots, diagnose root causes, and deliver practical, data-driven solutions. Proven track record leading finance and accounting functions, strengthening internal controls, and partnering cross-functionally to improve performance and execution.

Mr. Wu holds a MBA from National Central University (Taiwan). 

Dr. Foo has 17 years of clinical operations experience with Novartis, PPD, and PAREXEL, managing global and Asia-Pacific clinical trials in Ophthalmology, Oncology, Neuroscience, and Gene Therapy. He holds a Ph.D. in Pharmaceutics from the University of Iowa and B.Pharm (Hons) from Cardiff University, complemented by executive education from INSEAD, Digital Transformation & Change Management certification from BCG U, and Advanced Certificate in Generative AI, Ethics and Data Protection from Singapore Management University. Dr. Foo has led global clinical trial teams from study startup through regulatory submission for the approval of BEOVU®, Lucentis®, Zolgensma®, and Pluvicto™ expanded indications, managing clinical trial budgets up to $42 million per study.

Jessica Lee received her Biotechnology M.S. degree from Northwestern University and M.B.A. degree from China Europe International Business School. Jessica's life science experience spans over 12 years in different roles from researcher, venture capitalist to corporate development. Prior to Acepodia, she held business development positions at CytomX Therapeutics, WuXi Biologics and Eureka Therapeutics where she has successfully either led or facilitated fundraising events and licensing deals with multinational pharmaceutical companies, including Sanofi, Regeneron and Moderna.

Carolyn Bertozzi, Ph.D. was awarded the 2022 Nobel Prize in Chemistry for discovering a novel form of click chemistry, known as bioorthogonal chemistry. The revolutionary approach utilizes, bioorthogonal reactions that transpire inside living organism, seamlessly integrating with cellular functions without disrupting the normal functions of a cell. She advanced these reactions that are now used to explore cells, track biological processes and improve disease targeting in cancer more efficiently, moving click chemistry into living organisms. Dr. Bertozzi is the Anne T. and Robert M. Bass Professor of Chemistry at Stanford University and an investigator at the Howard Hughes Medical Institute. She is a member of the National Academy of Sciences, National Academy of Medicine and National Academy of Inventors and has been a significant leader in advancing novel approaches to treating a variety of diseases, including cancer.

Dr. Hsiao is the Chief Executive Officer, President and Co-Founder of Acepodia. He was awarded Dr. Y-T Lee Prize, which named after Nobel Laureate Dr. Lee, for his research achievement in Chemistry. Dr. Hsiao has extensive research experience in immune cell therapy development, which led to the discovery and invention of Acepodia’s novel cellular immunotherapy development platform, ACC (Antibody-Cell Conjugation) which was from Nobel Prize laureate-Professor Carolyn Bertozzi's pioneering work in the development of biorthogonal chemistry when Dr. Hsiao, Ph.D., worked at her lab. Dr. Hsiao earned his B.S. in Chemistry from National Taiwan University, and his Ph.D. in Chemistry and Molecular Cell Biology from the University of California, Berkeley.

Samuel Chen, Director at Digital Mobile Venture, currently serves on the Acepodia Board of Directors, holding his stake in Acepodia through Digital Mobile Venture. With extensive experience in strategic leadership and corporate governance, Mr. Chen contributes valuable insights to Acepodia’s decision-making and long-term vision. His leadership and industry expertise play a key role in driving the company's growth and strategic direction.

Carolyn Bertozzi, Ph.D. was awarded the 2022 Nobel Prize in Chemistry for discovering a novel form of click chemistry, known as bioorthogonal chemistry. The revolutionary approach utilizes, bioorthogonal reactions that transpire inside living organism, seamlessly integrating with cellular functions without disrupting the normal functions of a cell. She advanced these reactions that are now used to explore cells, track biological processes and improve disease targeting in cancer more efficiently, moving click chemistry into living organisms. Dr. Bertozzi is the Anne T. and Robert M. Bass Professor of Chemistry at Stanford University and an investigator at the Howard Hughes Medical Institute. She is a member of the National Academy of Sciences, National Academy of Medicine and National Academy of Inventors and has been a significant leader in advancing novel approaches to treating a variety of diseases, including cancer.

Dr. Hsiao-Ling Hung is an accomplished regulatory affairs expert with over two decades of pharmaceutical industry experience spanning regulatory strategy, R&D, and global health authority engagement. She has successfully led end-to-end regulatory pathways from preclinical development to NDA/BLA approvals across multiple therapeutic areas, including first-in-class and breakthrough therapies such as Balversa® and multiple indications for Opdivo®. As Acepodia’s regulatory consultant, Dr. Hung brings a proven track record in securing critical FDA designations, orchestrating global submission strategies, and guiding cross-functional teams through complex regulatory landscapes. Her deep scientific background, strategic insight, and collaborative leadership ensure that regulatory plans are aligned with both scientific innovation and commercial objectives.

Dr. Hsiao-Ling received a B.S. in Medical Technology from the National Taiwan University and a Ph.D. in Pathology and Molecular Biology from the University of Pennsylvania. 

Dr. Ken Chang has over 30 years of experience in biopharmaceutical industry with hands-on expertise in various phases of drug development and approval process that include discovery, product/process/assay/cell line development, protein characterization, fermentation, scale-up production, cGMP compliance, validation, quality control, quality assurance and regulatory submission.

Targeted drug delivery using radioimmunoconjugates, antibody-drug conjugates, enzyme-antibody conjugates, bispecific antibodies, T-cell redirected bispecific antibodies, engineered antibodies, recombinant immunotoxins, CAR-T and CAR-NK cells

Co-inventor and key architecture of the DOCK-AND-LOCK (DNL) platform technology

Oversaw the development of CEA-Scan and LeukoScan, resulting in approval by CPMP and FDA for CEA-Scan in 1996 and by CPMP for LeukoScan in 1997

A member on the 1988 ad hoc committee organized by professor Claude Meares for American Chemical Society, which resulted in recommending the creation of Bioconjugate Chemistry

A member on the International Editorial Advisory Board of Bioconjugate Chemistry from its launch in 1990 to 2016

A reviewer for various NIH study sections (2007-2013)

An invited speaker to present DNL-related topics at meetings organized by Cambridge Healthtech Institute (CHI)

A total of 114 publications in peer-reviewed journal.

To date, more than 21 patents have been issued on the DNL platform technology, among which US 7,521,056, titled “Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities”; and US 9,315,567, titled “T-cell redirecting bispecific antibodies for treatment of diseases”; have won the 2012 and 2016 Thomas Alva Edison Patent Award in the Biotechnology category, respectively.

Dr. Richard Lopez is Associate Professor of Medicine at Duke University and is also CEO and Founder of PhosphoGam, a biotechnology company developing gamma delta T cell therapies. Dr. Lopez is an experienced medical oncologist specializing in hematology and stem cell therapies.

Dr. Lopez graduated and completed his residency training both in Stanford University School of Medicine.

Dr. Yang is the Chairman and Co-Founder of Acepodia. Dr. Yang was formerly Executive Vice President at Juno Therapeutics. Prior to Juno, he served as Executive Vice President of Technical Operations at Roche and Genentech, where he was responsible for biopharmaceutical manufacturing, process development, engineering, technical regulatory, quality, procurement, and global supply chain management. Prior to Genentech, he served in various leadership roles in the industry with Merck, General Electric and Life Systems. Dr. Yang earned his B.S. in Engineering from National Chiao Tung University (Taiwan), his M.S. from the University of Cincinnati, and his Ph.D. in Engineering from Ohio State University.